The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
RSV-A neutralizing titers expressed as group Geometric Mean Titers (GMTs)
Timeframe: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
RSV-A neutralizing titers expressed as group Seroresponse rate (SRR)
Timeframe: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
RSV-B neutralizing titers expressed as group GMTs
Timeframe: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
RSV-B neutralizing titers expressed as group SRR
Timeframe: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)